Thoracic Malignancy Steering Committee
The NCI Thoracic Malignancy Steering Committee (TMSC) was established in 2008. Members of the TMSC include all Cooperative Group lung/thoracic disease committee chairs, Specialized Programs of Research Excellence (SPORE), Cancer Center and R01/P01 translational science investigators along with community oncologists, biostatisticians, patient advocates and NCI staff.
The TMSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in clinical research of lung and other thoracic malignancies by addressing the design and prioritization of phase III trials and large phase II studies in chest malignancies. In addition to focusing on lung cancer, the TMSC addresses oncology trials in other thoracic sites, such as mesothelioma. Esophageal cancer trials are reviewed by the Gastrointestinal Cancer Steering Committee.
Roster of Thoracic Malignancy Steering Committee (TMSC) members
A. William Blackstock, M.D., and David H. Harpole Jr., M.D., - Co-chairs
Clinical Trials Planning Meetings (CTPMs)
The Goal of CTPMs is to:
- identify strategic directions for clinical trials in a specific field
- reach consensus on the most important clinical trials to conduct;
- identify portfolio gaps and emerging scientific opportunities;
- identify innovative trial design opportunities;
- facilitate innovation and collaboration among the broad oncology community active in the specific cancer under study
- RTOG-0937: Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC) (NCT01055197)
To search all active clinical trials, go to: http://www.cancer.gov/clinicaltrials/search
CCCT Contact: Susan Rossi, Ph.D.